Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
Gelhaus has a proven track record of driving business growth
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
David joins HCTI with a distinguished career of over 22 years of corporate finance experience
Mantri will replace V. S. Mani, Executive Director & Global Chief Financial Officer of the company as he has conveyed his decision to opt for early retirement
In light of the contributions of these three institutes, it was decided to organize a CSIR Startup Conclave in Hyderabad. The event, scheduled for April 22–23, 2025
Subscribe To Our Newsletter & Stay Updated
